Krystal Biotech Valuation
Is 4KB undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 4KB when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: 4KB (€169.65) is trading below our estimate of fair value (€472.3)
Significantly Below Fair Value: 4KB is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 4KB?
Key metric: As 4KB is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.
| What is 4KB's PE Ratio? | |
|---|---|
| PE Ratio | 104.6x |
| Earnings | US$52.37m |
| Market Cap | US$5.48b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 19.8x |
| Enterprise Value/EBITDA | 69.3x |
| PEG Ratio | 2.5x |
Price to Earnings Ratio vs Peers
How does 4KB's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 49.1x | ||
BIO3 Biotest | 15.8x | 29.3% | €1.4b |
FYB Formycon | 12.9x | 31.5% | €827.2m |
2INV 2invest | 12.7x | n/a | €63.8m |
TLX Telix Pharmaceuticals | 154.9x | 38.3% | AU$7.6b |
4KB Krystal Biotech | 104.6x | 41.2% | €5.5b |
Price-To-Earnings vs Peers: 4KB is expensive based on its Price-To-Earnings Ratio (104.6x) compared to the peer average (48.8x).
Price to Earnings Ratio vs Industry
How does 4KB's PE Ratio compare vs other companies in the European Biotechs Industry?
| 5 Companies | Price / Earnings | Estimated Growth | Market Cap |
|---|---|---|---|
| 5 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Earnings vs Industry: 4KB is expensive based on its Price-To-Earnings Ratio (104.6x) compared to the European Biotechs industry average (27x).
Price to Earnings Ratio vs Fair Ratio
What is 4KB's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 104.6x |
| Fair PE Ratio | n/a |
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate 4KB's Price-To-Earnings Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | n/a | €190.18 0% | 4.2% | €202.28 | €178.48 | n/a | 9 |
| Nov ’25 | n/a | €190.33 0% | 4.0% | €202.99 | €177.27 | n/a | 9 |
| Oct ’25 | n/a | €187.95 0% | 4.0% | €200.45 | €175.05 | n/a | 9 |
| Sep ’25 | €175.10 | €185.89 +6.2% | 3.4% | €199.96 | €174.63 | n/a | 9 |
| Aug ’25 | n/a | €174.67 0% | 8.8% | €191.21 | €140.65 | n/a | 9 |
| Jul ’25 | n/a | €175.51 0% | 8.5% | €193.15 | €142.08 | n/a | 10 |
| Jun ’25 | n/a | €175.51 0% | 8.5% | €193.15 | €142.08 | n/a | 10 |
| May ’25 | n/a | €177.40 0% | 9.2% | €195.75 | €143.99 | n/a | 10 |
| Apr ’25 | €156.00 | €170.60 +9.4% | 9.0% | €190.88 | €140.41 | n/a | 10 |
| Mar ’25 | €156.00 | €168.60 +8.1% | 9.2% | €191.94 | €141.19 | n/a | 10 |
| Feb ’25 | n/a | €141.26 0% | 9.2% | €165.11 | €119.25 | n/a | 10 |
| Jan ’25 | n/a | €141.26 0% | 9.2% | €165.11 | €119.25 | n/a | 10 |
| Dec ’24 | n/a | €139.06 0% | 7.2% | €153.52 | €118.79 | n/a | 11 |
| Nov ’24 | n/a | €141.98 0% | 7.4% | €157.55 | €121.91 | n/a | 10 |
| Oct ’24 | n/a | €139.13 0% | 7.7% | €156.61 | €121.19 | n/a | 8 |
| Sep ’24 | €115.00 | €135.72 +18.0% | 8.2% | €153.47 | €118.76 | €175.10 | 7 |
| Aug ’24 | €114.00 | €126.45 +10.9% | 12.7% | €147.22 | €92.01 | n/a | 7 |
| Jul ’24 | n/a | €126.45 0% | 12.7% | €147.22 | €92.01 | n/a | 7 |
| Jun ’24 | €109.00 | €126.78 +16.3% | 11.6% | €144.63 | €93.31 | n/a | 8 |
| May ’24 | n/a | €101.53 0% | 10.2% | €120.70 | €90.75 | n/a | 8 |
| Apr ’24 | €74.50 | €107.04 +43.7% | 9.7% | €124.74 | €93.79 | €156.00 | 8 |
| Mar ’24 | €78.00 | €107.04 +37.2% | 9.7% | €124.74 | €93.79 | €156.00 | 8 |
| Feb ’24 | n/a | €98.70 0% | 14.8% | €122.40 | €72.70 | n/a | 8 |
| Jan ’24 | n/a | €102.33 0% | 14.3% | €128.40 | €76.27 | n/a | 8 |
| Dec ’23 | n/a | €102.33 0% | 14.3% | €128.40 | €76.27 | n/a | 8 |
| Nov ’23 | n/a | €99.23 0% | 15.2% | €126.17 | €71.82 | n/a | 8 |
Analyst Forecast: Target price is less than 20% higher than the current share price.
Discover undervalued companies
Aspen Pharmacare Holdings
R75.5b
Manufactures and supplies specialty and branded pharmaceutical products worldwide.
LDZA
R8.95
7D
0.6%
1Y
4.7%
Amneal Pharmaceuticals
US$2.6b
Develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide.
2DT
US$7.70
7D
-4.3%
1Y
91.5%
Almirall
€1.8b
A biopharmaceutical company, engages in the purchase, manufacture, storage, and sale of skin-health medicines in Europe, the Middle East, the United States, Asia, and Africa.
E2Z
€8.29
7D
-1.8%
1Y
0.2%